SCANCELL HOLDINGS PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.425 GBX | -1.82% |
|
-2.33% | -10.24% |
| Mar. 26 | Scancell doses first patient in melanoma-focused trials | AN |
| Mar. 22 | Seneca Growth Capital announces tepid 2023 results | AN |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 78.7M 97.91M |
|---|---|---|---|---|---|
| Net income 2024 * | -14M -17.42M | Net income 2025 * | -14M -17.42M | EV / Sales 2024 * | - |
| Net Debt 2024 * | 3.88M 4.82M | Net Debt 2025 * | 14.94M 18.59M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-5.34
x | P/E ratio 2025 * |
-6.35
x | Employees | 51 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.52% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.82% | ||
| 1 week | -2.33% | ||
| Current month | -8.05% | ||
| 1 month | -8.05% | ||
| 3 months | -12.33% | ||
| 6 months | -31.45% | ||
| Current year | -10.24% |
1 week
9.30
9.80
1 month
9.3011.10
Current year
9.3012.50
1 year
7.5918.30
3 years
7.5929.40
5 years
3.5029.40
10 years
0.1145.24
| Managers | Title | Age | Since |
|---|---|---|---|
Linda Durrant
CEO | Chief Executive Officer | 67 | 96-12-31 |
| Director of Finance/CFO | 38 | 23-08-28 | |
Fayaz Master
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 65 | 23-01-31 | |
Ursula Ney
BRD | Director/Board Member | 72 | 19-10-22 |
Linda Durrant
CEO | Chief Executive Officer | 67 | 96-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 9.425 | -1.82% | 319 221 |
| 24-04-22 | 9.6 | 0.00% | 148,421 |
| 24-04-19 | 9.6 | +0.52% | 244,525 |
| 24-04-18 | 9.55 | 0.00% | 246,518 |
| 24-04-17 | 9.55 | -1.04% | 256,648 |
Delayed Quote London S.E., April 23, 2024 at 11:25 am EDT
More quotes
Scancell Holdings plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is a developer of immunotherapies for the treatment of cancer and infectious diseases. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its products pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2 & iSCIB2, SCOV1 and SCOV2 (COVIDITY), as well as Anti-glycan antibodies. Modi-1, which targets citrullinated cancer antigens, is the first therapeutic vaccine candidate to emerge from Scancell's Moditope platform. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company's Moditope platform. SCIB1 is the lead product from its ImmunoBody immunotherapy platform, which identifies, attacks and destroys tumors. The COVIDITY program, focuses on the Company's COVID-19 vaccine candidates, SCOV1 and SCOV2.
Calendar
09:45am
- Immuno-Oncology Summit
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.096
GBP
Average target price
0.2473
GBP
Spread / Average Target
+157.64%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.24% | 97.08M | |
| +2.11% | 42.11B | |
| +49.22% | 40.08B | |
| +8.43% | 40B | |
| -10.82% | 26.87B | |
| +7.65% | 24.58B | |
| -22.75% | 18.44B | |
| +2.26% | 11.94B | |
| +31.83% | 11.66B | |
| +7.96% | 11.01B |
- Stock Market
- Equities
- SCLP Stock
